SCHEMBL2634071

SCHEMBL2634071

COc1ccccc1NC(=O)N(S)c1ncccc1Br

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.50
ALDH1A1 P00352 3/20 0.50
KDM4E B2RXH2 3/20 0.50
HTT P42858 2/20 0.50
RAB9A P51151 2/20 0.50
TSHR P16473 2/20 0.50
ALOX15 P16050 1/20 0.50
GFER P55789 1/20 0.50
NPC1 O15118 1/20 0.50
MAPT P10636 2/20 0.46
GAA P10253 2/20 0.46
AHR P35869 2/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
ALOX12 P18054 1/20 0.44
POLB P06746 1/20 0.44
USP2 O75604 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2634945 0.81 RAB9A (0.49) SMN1; SMN2ALDH1A1KDM4EHTTRAB9A
SCHEMBL6126215 0.77 SMN1; SMN2 (0.50) SMN1; SMN2ALDH1A1KDM4EHTTRAB9A
SCHEMBL3233774 0.73 KCNQ3 (0.45) ALDH1A1
SCHEMBL2251909 0.72 SMN1; SMN2 (0.43) SMN1; SMN2ALDH1A1HTTRAB9ATSHR
SCHEMBL2634070 0.71 SMN1; SMN2 (0.64) SMN1; SMN2ALDH1A1KDM4EHTTRAB9A
SCHEMBL7088595 0.71 ALDH1A1 (0.57) SMN1; SMN2ALDH1A1HTTRAB9ANPC1
SCHEMBL30163598 0.71 ALDH1A1 (0.57) SMN1; SMN2ALDH1A1HTTRAB9ANPC1
SCHEMBL7945599 0.70 RAB9A (0.61) SMN1; SMN2ALDH1A1HTTRAB9ANPC1
SCHEMBL6816160 0.70 HTT (0.55) SMN1; SMN2ALDH1A1HTTRAB9ANPC1
SCHEMBL6877180 0.69 SMN1; SMN2 (0.43) SMN1; SMN2ALDH1A1KDM4EHTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633173-B2 Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives CEPHALON, INC (US) 2014-01-21 US disclosed
US-20130296312-A1 Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives CEPHALON, INC. 2013-11-07 US disclosed
US-8501936-B2 Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives CEPHALON, INC. (US) 2013-08-06 US disclosed
EP-2438066-A2 PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES Cephalon, Inc. (US) 2012-04-11 EP disclosed
US-20100311693-A1 Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives CEPHALON, INC. (US) 2010-12-09 US disclosed
WO-2010141796-A2 PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES CEPHALON, INC. (US) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296312-A1 Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives JAK2, JAK1, JAK3 SMN1; SMN2 3360/4885ALDH1A1 2303/4885KDM4E 1892/4885
US-20100311693-A1 Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives CCNA1, CCNY, RB1 SMN1; SMN2 3192/4885ALDH1A1 985/4885KDM4E 2264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.